- Patent Title: Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders
-
Application No.: US16642445Application Date: 2018-08-28
-
Publication No.: US11459320B2Publication Date: 2022-10-04
- Inventor: Scott Thompson , Adam Van Dyke , Craig Thomas , Patrick Morris
- Applicant: UNIVERSITY OF MARYLAND, BALTIMORE , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Applicant Address: US MD Baltimore; US MD Bethesda
- Assignee: UNIVERSITY OF MARYLAND, BALTIMORE,THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Current Assignee: UNIVERSITY OF MARYLAND, BALTIMORE,THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Current Assignee Address: US MD Baltimore; US MD Bethesda
- Agency: Wolter Van Dyke Davis, PLLC
- Agent Eugene Molinelli; Martha Cassidy
- International Application: PCT/US2018/048339 WO 20180828
- International Announcement: WO2019/046300 WO 20190307
- Main IPC: C07D417/14
- IPC: C07D417/14 ; A61P25/24 ; C07D261/08 ; C07D413/12 ; A61K9/19 ; A61K45/06
Abstract:
The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
Information query
